Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Creatine may increase DHT levels, potentially affecting hair loss, but experiences vary. Many users use finasteride to counteract potential effects.

Finasteride may cause elevated liver enzymes, potentially leading to liver issues, though this is rare. Users should monitor liver function and consider topical alternatives if liver sensitivity occurs.

The user shared impressive hair growth results after 100 days using finasteride, minoxidil, biotin, and saw palmetto, and plans to get a hair transplant. The conversation includes suggestions for additional treatments like ketoconazole and derma stamping, and discussions about potential side effects of finasteride.

Creatine may cause hair shedding in some individuals, but there is no strong scientific evidence linking it to hair loss. Many users report personal experiences of increased hair loss with creatine, while others see no effect; OP is considering creatine while using finasteride and topical minoxidil for hair loss.

Switching from finasteride to dutasteride can improve hair regrowth with fewer side effects for some users. Concerns about shedding, lack of improvement, and the long-term safety of oral minoxidil remain.

Hair provides protection against head trauma, reduces skin cancer risk, helps remove heavy metals, and aids in wound healing. The conversation emphasizes the health benefits of maintaining head hair beyond cosmetic reasons.

Topical dutasteride is more effective than oral finasteride for male pattern hair loss, with fewer side effects. Some prefer oral treatments for convenience, while others use topical solutions like minoxidil and dutasteride, sometimes with microneedling, for better results.

Finasteride is generally seen as more successful for hair loss than Dutasteride, with fewer negative experiences reported. Dutasteride is considered more effective but often leads to more complaints, possibly due to higher expectations or improper use.

Finasteride is discussed as a hair loss treatment with benefits like reduced prostate enlargement and skin aging, but it is not seen as a "fountain of youth." Users report mixed experiences, including side effects like decreased libido and dry eyes.

Hair loss treatments like minoxidil, finasteride, TDM-105795, and PP405. MIT is hosting a hackathon to find innovative hair loss solutions.

A user shared their 8-month progress using 1mg oral finasteride with no side effects and plans to start minoxidil. Another user commented that the results look great and suggested reconsidering starting minoxidil.

Pyrilutamide shows minimal systemic absorption with low plasma levels and no accumulation, suggesting it's unlikely to cause systemic side effects. However, full results are not yet published in scientific journals.

Oral minoxidil can cause cardiovascular issues, but an extended release formulation may reduce side effects like heart rate and blood pressure spikes. This new formulation offers a safer option for those who previously had to stop due to health concerns.

Topical Clascoterone showed a 539% improvement in hair count compared to placebo, but its effectiveness and safety are debated. Users compared it to minoxidil and finasteride, with mixed opinions on its potential release in 2026 or 2027.

Combining Minoxidil with peptide serums like Redensyl, Procapil, and Capixyl is more effective for hair growth than using Minoxidil alone, increasing hair density and thickness. However, some users are skeptical about the effectiveness of peptides, suggesting other ingredients or factors might contribute to the results.

Dutasteride 2.5mg is more effective for vertex hair regrowth than finasteride and lower doses of dutasteride, with effects lasting longer after discontinuation. Finasteride's effectiveness decreases after 36 weeks, and sexual side effects are similar between the two treatments.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.

A 29-year-old male experienced significant hair regrowth over 8 months using a protocol of oral Minoxidil, Dutasteride, Pyrithione Zinc Shampoo, and peptides GHK-CU, BPC-157, and TB-500. The treatment led to improved scalp coverage, reduced hair loss, and thicker hair, although results may vary for others.

ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.

A user shared their successful experience with hair regrowth and transitioning from male to female using minoxidil, finasteride, Nutrafol, microneedling, and hormone replacement therapy (HRT). They expressed gratitude for the results and encouraged others to explore treatments that align with their personal goals.

A satirical post where someone claims to have developed a radioactive isotope scalp serum using Polonium-210 that outperforms Minoxidil and finasteride for hair regrowth. The serum reportedly stimulates DNA repair in hair follicles, leading to significant hair density increase, but the post is met with skepticism and concerns about safety.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

The conversation discusses the effectiveness of RU58841 and pyrilutamide for hair loss treatment. It seeks personal success or failure stories and scientific data on these treatments.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.